

"EXPRESS MAIL" MAILING LABEL NUMBER
DATE OF DEPOSIT 17 JANUARY 2002.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Blackburn et al. Group Art Unit No.:
Serial No.: Examiner:
Filed: 16 January 2002 Attorney Docket No.: P50438D2
For: ANTICOAGULANT AGENTS USEFUL IN TREATMENT OF THROMBOSIS

PRELIMINARY AMENDMENT

Prior to substantive examination, please amend the above-identified application as follows.

In the specification:

Please insert the following before the first sentence on page 1:

"This application is a divisional of Application Serial No. 09/344,050, filed 25 June 1999, which is a divisional of Application Serial No. 08/783,853, filed 16 January 1997, now U.S. Patent No. 6,005,091, which claims the benefit of U.S. Provisional Application No. 60/010,108, filed 17 January 1996, and U.S. Provisional Application No. 60/029,119, filed 24 October 1996."

In the claims:

Please cancel claims 3-5, 8, 9, and 11-38, without prejudice.

Please amend the claims as follows:

1. (Amended) A method for inhibiting thrombosis in an animal comprising administering an effective dose of an anti-coagulation factor IX/IXa monoclonal antibody.

6. (Amended) The method of claims 1 or 2 wherein the anti-Factor IX monoclonal antibody has the identifying characteristics of SB 249413, SB 249415, SB 249416, SB 2249417, SB 257731 or SB 257732.

7. (Amended) The method of claims 1 or 2 wherein the anti-Factor IX monoclonal antibody has the identifying characteristics of SB 249417.

Add the following new claims:

--39. The method of claim 10 wherein the thrombosis is associated with stroke.

40. The method of claim 10 wherein the thrombosis is associated with sepsis.

41. The method of claim 1 wherein the anti-coagulation Factor IX/IXa antibody binds with an epitope of the Factor IX gla domain.

42. The method of claim 41 wherein the epitope is located within residues 3-11 of Factor IX.

43. The method of claim 42 wherein the antibody has a binding affinity of at least 4 nM.--

Remarks


Claims 1, 2, 6, 7, 10 and 39-43 are pending in this application after entry of this Amendment.

Claim 1 has been amended to more particularly point out and distinctly define the invention. Claims 6 and 7 have been amended to change their dependency from a now-cancelled claim. New claims 39-43 have been added.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captions "Version with Marking to Show Changes Made."

Entry of this amendment is respectfully requested.

Respectfully submitted,



Kirk Baumeister
Attorney for Applicants
Registration No. 33,833

GLAXOSMITHKLINE

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone: (610) 270-5096

Fax: (610) 270-5073

n:\kb\ptodocs\p50438d2\pmam

"Version with Marking to Show Changes Made."

In the claims:

Claim 1 has been amended as follows:

1. (Amended) A method for inhibiting thrombosis in an animal comprising administering an effective dose of an anti-coagulation factor IX/IXa monoclonal antibody [having self-limiting neutralizing activity].

6. (Amended) The method of [claim 5] claims 1 or 2 wherein the anti-Factor IX monoclonal antibody has the identifying characteristics of SB 249413, SB 249415, SB 249416, SB 2249417, SB 257731 or SB 257732.

7. (Amended) The method of [claim 5] claims 1 or 2 wherein the anti-Factor IX monoclonal antibody has the identifying characteristics of SB 249417.

Claims 3-5, 8, 9, and 11-38 were canceled.

New claims 39-43 were added.